Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIROX in locally-advanced pancreatic cancer
NCT03316326Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2017
- Primary completion
- Dec 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of tegafur + gimeracil + oteracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03316326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316326.